Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06622070 · ClinicalTrials.gov registry record · Phase 1
A Study of SPY002-072 in Healthy Volunteers
A Phase 1 study of Healthy, sponsored by Spyre Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 2
- Study locations
NCT06622070: Recruiting Phase 1 study of Healthy, sponsored by Spyre Therapeutics.
NCT06622070 is a Phase 1 study of Healthy that is actively recruiting participants, run by Spyre Therapeutics. The registered enrollment target is 56 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06622070, a Phase 1 study of Healthy, is actively recruiting participants, sponsored by Spyre Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants.
Primary Outcome
Incidence, severity, and causal relationship of TEAEs
Conditions Studied
Interventions
- OTHER Placebo
- DRUG SPY002-072
Study Locations (2)
California
- Spyre Site 2 - Cypress
Quebec
- Spyre Site 1 - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2026-08-08 |
| Phase | Phase 1 |
What NCT06622070 shows while recruiting
NCT06622070 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06622070 reports a single indexed study location in California, Quebec.
Frequently Asked Questions
What is clinical trial NCT06622070 about?
NCT06622070 is a clinical study titled "A Study of SPY002-072 in Healthy Volunteers". This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants.
What is the current status of trial NCT06622070?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2024-11-18. Estimated completion is 2026-08-08.
What conditions does trial NCT06622070 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT06622070?
The interventions under investigation include: Placebo (OTHER), SPY002-072 (DRUG).
Who is sponsoring clinical trial NCT06622070?
This trial is sponsored by Spyre Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06622070 being conducted?
This trial has 2 study locations across California, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06622070's enrollment target sits among peer trials
56 413th of 1090 higher than 665 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI